TU Ilmenau Humbold Bau

Projektsuche


€

0 Projekte gefunden.


Nach den folgenden Parametern kann sortiert werden:

Titel
Hochschule
Fakultät/Einrichtung
Drittmittelgeber
Beginn Ende
Gesamtmittel
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer
UKJ
Medizinische Fakultät
Bayer AG
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
UKJ
Medizinische Fakultät
Universitätsklinikum Heidelberg
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
UKJ
Medizinische Fakultät
Incyte Corporation
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
UKJ
Medizinische Fakultät
Cytokinetics, Inc.
2024 - 2025
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
UKJ
Medizinische Fakultät
Chinook Therapeutics, Inc.
2024 - 2026
Kategorie 100.000,00 - 499.999,00 €
A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study toEvaluate the Safety and Efficacy of Bomedemstat (MK-3543) versus Hydroxyurea inParticipants with Previously-Untreated Essential Thrombocythemia
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2030
Kategorie 100.000,00 - 499.999,00 €
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) PlusPembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatmentof Participants With Renal Cell Carcinoma
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2030
Kategorie 100.000,00 - 499.999,00 €
A Phase 2, adaptive, randomized, open-label, assessorblinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
UKJ
Medizinische Fakultät
Novartis Pharma GmbH
2024 - 2029
Kategorie 100.000,00 - 499.999,00 €
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
UKJ
Medizinische Fakultät
MSD SHARP & DOHME GmbH
2024 - 2028
Kategorie 100.000,00 - 499.999,00 €
CoNAN - Studie zum CoVID-19-Ausbruch in Neustadt am Rennsteig
UKJ
Medizinische Fakultät
TMWWDG
2020 - 2021
499.700,00 €
Projektsuche | Impressum | FAQ